Media stories about Derma Sciences (NASDAQ:DSCI) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Derma Sciences earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 46.4984059862139 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Derma Sciences (NASDAQ:DSCI) remained flat at $$7.00 during midday trading on Friday. 57,400 shares of the stock were exchanged, compared to its average volume of 719,592. Derma Sciences has a twelve month low of $2.92 and a twelve month high of $7.05.
COPYRIGHT VIOLATION WARNING: “Derma Sciences (DSCI) Earns Media Sentiment Rating of 0.13” was posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://transcriptdaily.com/2017/12/01/derma-sciences-dsci-earns-media-sentiment-rating-of-0-13.html.
Derma Sciences Company Profile
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.